Skip to main content

Advertisement

SpringerLink
Log in

DNA repair inhibitors in cancer treatment

  • Educational Series
  • Green Series
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Chemotherapy and radiation are two important modalities for cancer treatment. Many agents in clinical used have the ability to induce DNA damage, however they may be highly cytotoxic as a secondary effect. Different mechanisms are involved both, in detection and repair of DNA damage. The modulation of these pathways, has a great impact on clinical outcome and is frequently responsible of therapeutic resistance. Therefore, pharmacological inhibition of DNA damage repair pathways has been explored as a useful strategy to enhance chemo and radiosensitivity, thus it could be used for reversing drug resistance. Different agents have shown excellent results in preclinical studies in combination with radiation or chemotherapy. Early phase clinical trials are now being carried out using different DNA repair inhibitors targeting several enzymes such as PARP, DNA-PK or MGMT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ishikawa K, Ishii H, Saito T. DNA damage-dependent cell cycle checkpoints and genomic stability. DNA Cell Biol. 2006; 25:406–11.

    Article  PubMed  CAS  Google Scholar 

  2. Bentle MS, Bey EA, Dong Y, Reinicke KE, Boothman DA. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors. J Mol Histol. En prensa 2006.

  3. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic largets in cancer. Cancer Treat Rev. 2005; 31:603–17.

    Article  PubMed  CAS  Google Scholar 

  4. Daniels DS, Woo TT, Luu KX, et al. DNA binding and nucleotide flipping by the human DNA repair protein AGT. Nat Struct Mol Biol. 2004;11:714–20.

    Article  PubMed  CAS  Google Scholar 

  5. Maki Y, Murakami J, Asaumi J, et al. Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloplatinum (II) in oral cancer cell lines. Oral Oncol. 2005;41:984–93.

    Article  PubMed  CAS  Google Scholar 

  6. Quinn JA, Desjardins A, Weingart J, et al. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005;23:7178–87.

    Article  PubMed  CAS  Google Scholar 

  7. Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP. Effect of O6-(4-bromothenyl) guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer. 2002;100:615–7.

    Article  PubMed  CAS  Google Scholar 

  8. Kaina B, Muhlhausen U, Piee-Staffa A, et al. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther. 2004;311:585–93.

    Article  PubMed  CAS  Google Scholar 

  9. Madhusudan S, Smart F, Shrimpton P, et al. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res. 2005;33:4711–24.

    Article  PubMed  CAS  Google Scholar 

  10. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs. 2004;5:623–7.

    PubMed  CAS  Google Scholar 

  11. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4: 421–40.

    Article  PubMed  CAS  Google Scholar 

  12. Haince JF, Rouleau M, Hendzel MJ, Masson JY, Poirier GG. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med. 2005;11: 456–63.

    Article  PubMed  CAS  Google Scholar 

  13. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 2004;24:2127–54.

    PubMed  CAS  Google Scholar 

  14. Beneke S, Diefenbach J, Burkle A. Poly-(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions. Int J Cancer. 2004;111:815–8.

    Article  Google Scholar 

  15. Hu HY, Horton JK, Gryk MR, et al. Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping. J Biol Chem. 2004;279:39736–44.

    Article  PubMed  CAS  Google Scholar 

  16. Haber JE. Partners and pathwaysrepairing a double-strand break. Trends Genet. 2000;16:259–64.

    Article  PubMed  CAS  Google Scholar 

  17. Karran P. DNA double strand break repair in mammalian cells. Curr Opin Genet Dev. 2000;10:144–50.

    Article  PubMed  CAS  Google Scholar 

  18. Norbury CJ, Hickson ID. Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol. 2001;41:367–401.

    Article  PubMed  CAS  Google Scholar 

  19. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell. 2002;109 Suppl: 45–55.

    Article  Google Scholar 

  20. Bassing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst). 2004;5:781–96.

    Article  Google Scholar 

  21. Hickson I, Zhao Y, Richardson, CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004;64:9152–9.

    Article  PubMed  CAS  Google Scholar 

  22. Kao J, Milano MT, Javaheri A, et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006; 6(5): 197–205.

    Article  PubMed  CAS  Google Scholar 

  23. Hefferin ML, Tomkinson AE. Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair (Amst). 2005;4:639–48.

    CAS  Google Scholar 

  24. Miao ZH, Tong LJ, Zhang JS, Han JX, Ding, J. Characterization of salvicine-resistant lung adenocarcinoma A549/SAL cell line. Int J Cancer, 2004;110:627–32.

    Article  PubMed  CAS  Google Scholar 

  25. Plumb JA, Steele N, Finn PW, Brown R. Epigenetic approaches to cancer therapy. Biochem Soc Trans. 2004;32:1095–7.

    Article  PubMed  CAS  Google Scholar 

  26. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 2000;60:6039–44.

    PubMed  CAS  Google Scholar 

  27. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003;63:1550–4.

    PubMed  CAS  Google Scholar 

  28. Matheson SL, McNamee J, Jean-Claude BJ. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J Pharmacol Exp Ther. 2001;296:832–40.

    PubMed  CAS  Google Scholar 

  29. Matheson SL, McNamee JP, Jean-Claude BJ. Differential responses of EGFR-/AGT-expressing cells to the «combi-triazene» SMA41. Cancer Chemother Pharmacol. 2003;51:11–20.

    Article  PubMed  CAS  Google Scholar 

  30. Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ. Inhibition of epidermal growth factor receptor-mediated signaling by «Combi-triazene» BJ2000, a new probe for Combi-Targeting postulates. J Pharmacol Exp Ther. 2002;505:238–46.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto de Investigaciones Biomédicas del CSIC/UAM, Traslational Oncology Unit CSIC/Hospital La Paz, C/Arturo Duperier, 4, 28029, Madrid, Spain

    Isabel Sánchez-Pérez

Authors
  1. Isabel Sánchez-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Isabel Sánchez-Pérez.

Additional information

Supported by an unrestricted educational grant from Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sánchez-Pérez, I. DNA repair inhibitors in cancer treatment. Clin Transl Oncol 8, 642–646 (2006). https://doi.org/10.1007/s12094-006-0034-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-006-0034-8

Key words

Search

Navigation